Granted Patent B2

US 8,076,352 · App. 11/735,069 · Granted Dec 13, 2011

Abstract

Claims (39)

1. A method for inhibiting pathologically induced VEGF expression comprising administering a therapeutically effective amount of a compound of Formula (IV):

or a pharmaceutically acceptable salt, racemate or stereoisomer of said compound, to a subject in need thereof; wherein

X is hydrogen; C 1 to C 6 alkyl optionally substituted with one or more halogen substituents; hydroxyl; halogen; or C 1 to C 5 alkoxy optionally substituted with phenyl;

R o is hydrogen; halogen; cyano; nitro; sulfonyl substituted with C 1 to C 6 alkyl or morpholinyl; amino optionally substituted with C 1 to C 6 alkyl, —C(O)—R b , —C(O)O—R b , alkylsulfonyl, morpholinyl or tetrahydropyranyl; C 1 to C 6 alkyl optionally substituted with one or more substituents independently selected from hydroxyl, halogen or amino; —C(O)—R n ; or —OR a ;

R a is hydrogen; C 2 to C 8 alkenyl; —C(O)O—R b ; —C(O)—NH—R b ; C 1 to C 8 alkyl optionally substituted with one or more substituents independently selected from hydroxyl, halogen, C 1 to C 4 alkoxy, amino, alkylamino, dialkylamino, acetamide, —C(O)—R b , —C(O)O—R b , aryl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,3-dioxolan-2-one, oxiranyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3-triazole, 1,2,4-triazole, furan, imidazole, isoxazole, isothiazole, oxazole, pyrazole, thiazole, thiophene or tetrazole;

wherein amino is optionally substituted with C 1 to C 4 alkoxycarbonyl, imidazole, isothiazole, pyrazole, pyridine, pyrazine, pyrimidine, pyrrole, thiazole or sulfonyl substituted with C 1 to C 6 alkyl, wherein pyridine and thiazole are each optionally substituted with C 1 to C 4 alkyl;

wherein alkylamino and dialkylamino are each optionally substituted on alkyl with hydroxyl, C 1 to C 4 alkoxy, imidazole, pyrazole, pyrrole or tetrazole; and,

wherein morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidinyl, piperazinyl and oxiranyl are each optionally substituted with —C(O)—R n , —C(O)O—R n or C 1 to C 4 alkyl, wherein C 1 to C 4 alkyl is optionally substituted with hydroxyl;

R b is hydroxyl; amino; alkylamino optionally substituted on alkyl with hydroxyl, amino, alkylamino or C 1 to C 4 alkoxy; a C 1 to C 4 alkoxy; C 2 to C 8 alkenyl; C 2 to C 8 alkynyl; aryl optionally substituted with one or more substituents independently selected from halogen and C 1 to C 4 alkoxy; furan; or C 1 to C 8 alkyl optionally substituted with one or more substituents independently selected from C 1 to C 4 alkoxy, aryl, amino, morpholinyl, piperidinyl or piperazinyl;

R d is phenyl substituted with one or more substituents independently selected from hydrogen, halogen, nitro, C 1 to C 6 alkyl, —C(O)O—R e or —OR e ;

R e is hydrogen; C 1 to C 6 alkyl optionally substituted with one or more substituents independently selected from halogen and alkoxy; or phenyl optionally substituted with one or more substituents independently selected from halogen or alkoxy; and

R n is a hydroxyl, C 1 to C 4 alkoxy, amino or C 1 to C 6 alkyl,

wherein the administered compound inhibits pathologically induced VEGF expression as shown by an ELISA assay in HeLa cells or in a HT1080 solid tumor grown in a nude mouse, inhibits HT1080 solid tumor growth in a nude mouse or inhibits angiogenesis in a HT1080 solid tumor grown in a nude mouse.

2. A method for inhibiting pathologically induced VEGF expression comprising administering a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt, racemate or stereoisomer thereof.

3. The method of claim 1 , wherein said compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein said compound has a chiral carbon at the point of attachment of the R o substituted phenyl on the compound of Formula (IV) and said compound is an (S) isomer at said chiral carbon.

5. The method of claim 2 , wherein said compound has a carboline scaffold and a chiral carbon at the point of attachment of the optionally substituted phenyl ring on said scaffold, and wherein said compound is an (S) isomer at said chiral carbon.

6. The method of claim 1 , wherein inhibiting pathologically induced VEGF expression treats a solid tumor cancer.

7. The method of claim 1 , wherein the compound has an EC 50 of less than 50 μM for inhibiting hypoxia-induced VEGF expression in cultured HeLa cells.

8. The method of claim 1 , wherein the compound inhibits pathologically induced VEGF production in a HT1080 solid tumor grown in a nude mouse.

9. The method of claim 1 , wherein the compound inhibits HT1080 solid tumor growth in a nude mouse.

10. The method of claim 1 , wherein the compound inhibits angiogenesis in a HT1080 solid tumor grown in a nude mouse.

11. The method of claim 1 , wherein the compound inhibits pathologically induced VEGF production as shown by an ELISA assay in HeLa cells.

12. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

13. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

17. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

18. The method of claim 3 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (6)